CAR-T Followed by Bispecific Antibodies for Large B-cell Lymphoma

This study is testing the safety and effectiveness of two different drug combinations given after CAR T-cell therapy for people with large B-cell lymphoma that has come back or didn't respond to previous treatments. You might receive mosunetuzumab, or a combination of obinutuzumab and glofitamab. The goal is to see how many participants achieve a complete metabolic response (meaning no signs of cancer activity) at 24 weeks. This study is currently unclear about its recruitment status and plans to enroll 23 participants. To join, you must be at least 18 years old, have a life expectancy of at least 12 weeks, and have received prior treatments for your lymphoma.

Study design: This is an interventional study with an unclear phase, planning to enroll 23 participants. It is testing different drug combinations in cohorts after CAR T-cell therapy.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: The study assesses complete metabolic response at 24 weeks and dose-limiting toxicity at 63 days after the first infusion of glofitamab.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

CAR-T Followed by Bispecific Antibodies

Active, Not Recruiting

PHASE2Ages 18+InterventionalTreatment

Abramson Cancer Center at Penn Medicine

~23 participants

Updated 2026-09-14 on ClinicalTrials.gov

What's tested:mosunetuzumabglofitamabobinutuzumab

At a glance

Recruiting sites

0 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Assessment of the percentage of subjects who achieve a complete metabolic response at 24 weeks from date of first infusion as measured by Cheson 14 (ie Lugano) criteria

Measured over 24 weeks from date of first infusion of investigational agent

Conditions

Large B-cell Lymphoma

DLBCL - Diffuse Large B Cell Lymphoma

NCT04889716

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvaniano site contact published
University of Nebraska Medical Center
Omaha, Nebraskano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Stephen J. Schuster, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Life expectancy of at least 12 weeks

History of relapsed or refractory large B-cell lymphoma (including transformed follicular lymphoma, and follicular lymphoma Grade 3B) who have relapsed after or failed to respond to at least one prior standard systemic treatment regimen that contains an anthracycline and at least one containing an anti-CD20-directed therapy and for whom there is no available therapy expected to improve survival (e.g., standard chemotherapy, autologous or allogeneic stem cell transplant).

PET/CT scan (preferred), diagnostic CT scan, or MRI prior to CAR-T cell therapy, with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesion or ≥ 1cm for extra-nodal lesions in largest dimension by low-dose computerized tomography \[CT\] scan with FDG-uptake ≥ liver); this imaging must have been obtained within 56 days of receiving CAR T cell therapy.

PET/CT scan (preferred), diagnostic CT scan, or MRI with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesion or ≥ 1cm for extra-nodal lesions in largest dimension by low-dose computerized tomography \[CT\] scan with FDG-uptake ≥ liver); this imaging documenting measurable disease must be obtained at least day +28 after CAR T cell infusion and prior to cycle 1 day 1.

Be at least 30 days after CAR T-cell infusion at time of study enrollment.

Adequate laboratory studies,

Ability and willingness to take proper contraceptive precautions

Exclusion

Had \> Grade 3 cytokine release syndrome (CRS) by ASTCT criteria after CAR-T therapy or who have unresolved CRS after CAR-T therapy

Had ≥ grade 2 neurologic toxicity by ASTCT criteria after CAR-T therapy or who have active neurologic toxicity after CAR-T therapy

Inability to comply with protocol-mandated hospitalization and activities restrictions in the investigators' decision

Pregnant or lactating, or intending to become pregnant during the study or within 3 months after the last dose of bispecific antibody or 18 months of obinutuzumab, whichever comes later

Prior solid organ transplantation

Active systemic autoimmune disease or other disease requiring chronic immunosuppressive therapy

History of confirmed progressive multifocal leukoencephalopathy (PML)

History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)

History of other malignancy that could affect compliance with the protocol or interpretation of results

Significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina)

Significant active pulmonary disease (e.g., bronchospasm and/or obstructive pulmonary disease) requiring oxygen or corticosteroid use.

Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major documented infection requiring treatment with IV antibiotics or hospitalization within 2 weeks prior to first mosunetuzumab or glofitamab administration. Empiric or prophylactic antibiotics administered during neutropenia or neutropenic fever without microbiologic evidence of infection do not exclude patients.

Recent major surgery within 4 weeks prior to first mosunetuzumab or glofitamab administration

Active or chronic infection(s) would have increased risks for toxicity if treated with bispecific antibody therapy, thus will be excluded.

Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study

Received systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of corticosteroid treatment \< 20 mg/day prednisone or equivalent within 2 weeks prior to first dose of bispecific antibody

History of drug or alcohol abuse within 12 months prior to screening in the investigator's judgment

Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's and/or Medical Monitor's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results

What this trial measures

Assessment of the percentage of subjects who achieve a complete metabolic response at 24 weeks from date of first infusion as measured by Cheson 14 (ie Lugano) criteria24 weeks from date of first infusion of investigational agent
Complete response will be assessed using Cheson 2014 or Lugano criteria, utilizing simple 5 point score (Deauville score). For this study complete response will be a score of 1 (no uptake), 2 (uptake ≤ mediastinum), or 3 (uptake \>mediastinum but ≤ liver, with no new lesions, and no FDG-uptake in the bone marrow, that is not expected (i.e. due to growth factors or therapy

Trialytics